Skip to main content

Table 2 Characteristics of patients with Pseudomonas aeruginosa ventilator-associated pneumonia at admission to the intensive care unit

From: Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa

Characteristics PSPA-VAP N = 153 PRPA-VAP N = 70 P a
Male sex 119 (78) 55 (79) 0.75
Age 68 (55 to 76) 66 (49 to 77) 0.54
Type of admission Medical 106 (69) 46 (66) 0.83
  Surgical 27 (18) 15 (21) 0.53
  Scheduled 20 (13) 9 (13) 0.65
SAPS II   48 (38 to 61) 48 (38 to 55) 0.80
Main diagnosis at admission Septic shock 23 (15) 20 (29) 0.02
  Multiple organ failure 8 (5) 4 (6) 0.79
  Cardiovascular failure 6 (4) 1 (1) 0.64
  Respiratory failure 55 (36) 19 (27) 0.14
  Acute respiratory exacerbation of chronic pulmonary diseases 9 (6) 5 (7) 0.61
  Acute renal failure 4 (3) 1 (1) 0.57
  Scheduled surgery 4 (3) 6 (9) 0.02
Treatments within 48 hrs of ICU admission Vasopressors 101 (66) 42 (60) 0.25
  Steroids 50 (33) 24 (34) 0.67
  Broad-spectrum antimicrobials 92 (60) 54 (77) 0.03
Duration of ICU stay before VAP 9 (6 to 17) 11 (6 to 18) 0.23
Organ dysfunction scores the day before VAP LOD 5 (3 to 7) 4.5 (3 to 7) 0.56
  SOFA 6 (3 to 8) 5 (3 to 7) 0.77
Polymicrobial VAP 45 (29) 18 (26) 0.53
Positive blood culture 6 (4) 7 (10) 0.11
Duration of stay ICU 29 (17 to 48) 28,5 (18 to 48) 0.37
  Hospital 47.5 (28 to 72) 50 (28 to 68) 0.24
  1. Data are the number (%) of patients (minimum to maximum). ICU, intensive care unit; LOD, logistic organ dysfunction; PRPA, piperacillin resistant Pseudomonas aeruginosa; PSPA, piperacillin sensitive Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score version II; SOFA, Simplified Organ Failure Assessment; VAP, ventilator-associated pneumonia.
  2. a Wald χ2 test in conditional regression